Effect of pegylated interferon treatments for chronic active hepatitis C on quality of life

Journal of Chemotherapy

Volumn 20, Issue 1, 2008, Pages 101-105

  Nayman Alpat, Saygin ^a   Usluer, G ^a   Yavuz, H ^b   Doyuk Kartal, E ^a   Erben, N ^a   Bal, C ^a   Ozgunes I ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^b Eskisehir Yunus Emre State Hospital   (Turkey)

Author keywords

Chronic hepatitis C; Health related quality of life; Pegylated interferon

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ARTICLE; CHI SQUARE TEST; CHRONIC ACTIVE HEPATITIS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; QUALITY OF LIFE; QUESTIONNAIRE; RANK SUM TEST; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 41149133459     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.1.101     Document Type: Article

References (14)

1. Alberti A, Benvegnu L. Management of hepatitis C. J Hepatol 2003; 38 (Suppl 1): 104-118.
2. Manns MP, Mc Hatchison JG, Gordon SC et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
3. Pearlman BL. Hepatitis C treatment update. Am J Med 2004; 117: 344-352.
4. Spiegel BMR, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. Hepatology 2005; 41: 790-800.
5. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35: 704-708.
6. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999; 29: 264-270.
7. Abacioglu YH, Davidson F, Tuncer S, Yap PL. Ustacelebi S, Yulug N, Simmonds P. The distribution of hepatitis C virus genotypes in Turkish patients. J Viral Hepat 1995; 2(6): 297-301.
8. Turhan V, Ardic N, Eyigun CP, Avci IY, Sengul A, Pahsa A. Investigation of the genotype distribution of hepatitis C virus among Turkish population in Turkey and various European countries. Chin Med J 2005; 118(16): 1392-1394.
9. Ware JE J, Snow KK, Kosinski M, Gandek B. SF-36 Health survey: manual and interpretation guide. The Health Institute, New England Medical Center; 1993.
10. Ware J, Kosinski M, Keller S. SF-36 Physical and mental health summary scores: a user's manual. The Health Institute, New England Medical Center; 1994.
11. McHutchison JG, Ware JE Jr, Bayliss MS et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34: 140-147.
12. Perrillo R , Rothstein KD, Rubin R et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat 2004; 11: 157-165.
13. Rasenack J, Zeuzem S, Feinman SV et al. Peginterferon alpha-2a (40 kD) [Pegasys ®] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon ®-A] In patients with chronic hepatitis C. Pharmacoeconomics 2003; 21: 341-349.
14. Hassenein T, Cooksley G, Sulkowski M et al. The impact of peginterferon alpha-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004; 40: 675-681.